ESMO 2016: Longer disease-free survival in phase III trial of sunitinib as adjuvant treatment for kidney cancer
A phase III trial of sunitinib has met its primary endpoint of disease-free survival for…
Browsing: ESMO 2016
ESMO 2016: Single-arm trials for early access to cancer drugs
Although randomised clinical trials (RCTs) remain the gold standard for evaluating the benefit/risk of cancer…
ESMO 2016: Niraparib significantly improves outcome of ovarian cancer patients in landmark trial
The PARP inhibitor niraparib significantly improves the outcome of platinum-sensitive recurrent ovarian cancer, according to…
ESMO 2016: Financial difficulties linked to worse outcomes from cancer treatment
Financial difficulties can significantly impact a cancer patient’s quality of life during treatment and may…
ESMO 2016: Significant survival gains from neoadjuvant chemo for high-risk soft tissue sarcoma
Neoadjuvant chemotherapy with an anthracycline plus ifosfamide was associated with significant survival gains in patients…